 The proposed clinical trial will enroll 20 HIV-infected adults who are on stable and effective antiretroviral therapy ART. The therapeutic regimen to be tested involves a combination of vaccinations DNA priming and MVA boosting, administration of broadly neutralizing antibodies bNAbs and a Toll-like receptor 9 TLR9 agonist. GeoVax will provide its novel boost component MVA62B for use in the studies. 